ERCC1 is not expressed in hepatocellular cancer: A Turkish Oncology Group, Gastrointestinal Oncology Subgroup study

Turhal N. S. , BAŞ E., Er O., Aliustaoglu M., Seber S., DANE F., ...More

JOURNAL OF BUON, vol.15, no.4, pp.794-796, 2010 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 4
  • Publication Date: 2010
  • Doi Number: 10.1007/s12032-010-9553-9
  • Title of Journal : JOURNAL OF BUON
  • Page Numbers: pp.794-796


Purpose: Hepatocellular cancer (HCC) is a common malignancy with a high mortality rate. Existence of excisional repair cross complementation1 (ERCC1) is implicated in resistance to cisplatin treatment. Expression of ERCC1 in HCC is not known. In this study we aimed to find out whether a subset of HCC patients can be identified to benefit from cisplatin.